Selina Koch

San Francisco

Executive Editor at BioCentury

Featured in: Favicon

biocentury.com Favicon

fm1today.ch Favicon

zephyrnet.com Favicon

argoviatoday.ch Favicon

baerntoday.ch Favicon

pilatustoday.ch

Articles

Alzheimer's Research Pulled Into Political Crossfire As NIH Cuts Accelerate

1 week ago | zephyrnet.com | Selina Koch

ARTICLE | Discovery & TranslationBy Selina Koch, Executive EditorAs it terminates NIH grants, the Trump administration has largely targeted politically charged areas such as DEI and COVID-19 research. Yet, Alzheimer's disease research - with no direct ties to these issues - has also been swept up in the purge, with more such projects, in Alzheimer's and other diseases, almost certain to follow.
Alzheimer’s research pulled into political crossfire as NIH cuts accelerate

1 week ago | biocentury.com | Selina Koch

ARTICLE | Discovery & TranslationAlzheimer’s research joins list of NIH-funded projects disrupted by terminations, freezes By Selina Koch, Executive EditorAs it terminates NIH grants, the Trump administration has largely targeted politically charged areas such as DEI and COVID research. Yet Alzheimer’s disease research — with no direct ties to these issues — has also been swept up in the purge, with more such projects, in Alzheimer’s and other diseases, almost certain to follow.
Biopharma indexes rally to end white-knuckle week

1 week ago | biocentury.com | Selina Koch

DATA GRAPHICS | Data ByteAfter series of tariff announcements continued to roil markets, Friday’s gains returned the XBI and NBI nearly to midweek highs By Paul Bonanos, Director of Biopharma IntelligenceBiotech indexes capped a volatile week with gains during Friday’s session, although their performance remains worse than the broader markets since President Trump announced widespread tariffs on April 2.
Amid Alzheon Alzheimer’s setback, PIs see new surrogate endpoint

3 weeks ago | biocentury.com | Selina Koch

ARTICLE | Product DevelopmentBut study’s PIs argue for hippocampal volume as a new surrogate endpoint By Selina Koch, Executive EditorAlzheon’s amyloid-targeting therapy has missed its efficacy endpoints in a Phase III Alzheimer’s trial, but the study’s PIs believe the molecule produced clinically meaningful benefit in a subgroup of early-stage patients. They argue the therapy’s efficacy is backed by a biomarker that could serve as a new surrogate endpoint.
CVRs heavily discounted in biopharma M&A deals: Data Byte

1 month ago | biocentury.com | Selina Koch

DATA GRAPHICS | Data ByteAfter a takeout is announced, the target company’s share price hews much closer to the deal price without the CVR than with it By Selina Koch, Executive EditorContingent value rights have once again become a popular way to bridge the valuation gap in negotiations for biopharma M&A transactions, but public investors appear to place little value on them, according to a BioCentury analysis.
Lundbeck’s next chapter: from psychiatry to rare neuro

1 month ago | biocentury.com | Selina Koch

ARTICLE | Product DevelopmentLeaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more By Selina Koch, Executive EditorWhile Lundbeck has yet to fully shake off its reputation as an old-school small molecule psychiatry play, the company is deep into a transformation that has taken it into other areas of neuroscience and new technology spaces.
Biotechs make inroads to precision medicine, solving long-standing problems

2 months ago | biocentury.com | Selina Koch

DATA GRAPHICS | Product Development70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas By Selina Koch, Executive EditorRecent drug approvals show small and medium-sized players are becoming increasingly successful at navigating the obstacles to get precision therapies across the FDA finish line. The data suggest pharma’s dominance in the area is not as absolute as it once was.
Vertex heads into new commercial territory with pain approval

2 months ago | biocentury.com | Selina Koch

ARTICLE | RegulationFDA approves Bay Area biotech’s Journavx, ushering in a new therapeutic mechanism for pain management By Selina Koch, Executive EditorFDA’s approval of Vertex’s acute pain medicine Journavx suzetrigine ushers in the first new therapeutic mechanism for pain management in ages. Whether Vertex can turn that scientific breakthrough into commercial success depends both on launch execution and its ability to expand the drug’s label into larger opportunities in chronic pain.
2025 catalysts: New mechanisms in obesity, neurology, ophthalmology

Jan 17, 2025 | biocentury.com | Selina Koch

ARTICLE | Product DevelopmentNew Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD By Lauren Martz, Executive Director, Biopharma Intelligence, and Selina Koch, Executive EditorAs the obesity pipeline swells, BioCentury has its sights this year on new mechanisms poised to deliver clinical proof of concept, as well as updates from the field’s leaders and next-gen players with compelling differentiation stories.
Rescuing stroke drug development: How NIH is leading the charge

Nov 22, 2024 | biocentury.com | Selina Koch

ARTICLE | Product DevelopmentThe first graduate of the institute’s preclinical stroke study is gearing up to enter its new clinical platform By Selina Koch, Executive EditorEvery 3 minutes and 14 seconds, someone dies of stroke in the U.S., yet drug developers largely abandoned the indication years ago. A string of clinical trial failures contributed to the retreat, which has led industry to virtually ignore the second-leading cause of death worldwide.